# Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

> **NCT00981045** · PHASE3 · COMPLETED · sponsor: **American Regent, Inc.** · enrollment: 2561 (actual)

## Conditions studied

- Iron Deficiency Anemia
- Impaired Renal Function

## Interventions

- **DRUG:** Ferric Carboxymaltose (FCM)
- **DRUG:** Iron Sucrose (Venofer)

## Key facts

- **NCT ID:** NCT00981045
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-07
- **Final completion:** 2011-08
- **Target enrollment:** 2561 (ACTUAL)
- **Last updated:** 2018-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981045, "Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT00981045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*